State Street’s iBio IBIO Stock Holding History

State Street’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$268K	Buy	141,199 +68,300	+94%	+$158K	﹤0.01%	3820
2025 Q4	$141K	Buy	72,899 +39,200	+116%	+$53.5K	﹤0.01%	3975
2025 Q3	$27.9K	Hold	33,699	–	–	﹤0.01%	4222
2025 Q2	$25.7K	Hold	33,699	–	–	﹤0.01%	4182
2025 Q1	$135K	Buy	+33,699	New	+$131K	﹤0.01%	3906
2023 Q4	–	Sell	-2,403	Closed	-$14.6K	–	4459
2023 Q3	$14.6K	Hold	2,403	–	–	﹤0.01%	4475
2023 Q2	$29.3K	Hold	2,403	–	–	﹤0.01%	4536
2023 Q1	$100K	Buy	2,403 +860	+56%	+$22.1K	﹤0.01%	4330
2022 Q4	$13.7K	Hold	1,543	–	–	﹤0.01%	4776
2022 Q3	$131K	Hold	1,543	–	–	﹤0.01%	4340
2022 Q2	$204K	Sell	1,543 -7,427	-83%	-$1.12M	﹤0.01%	4186
2022 Q1	$1.92M	Sell	8,970 -138	-2%	-$28.9K	﹤0.01%	3581
2021 Q4	$2.5M	Sell	9,108 -64	-0.7%	-$24.4K	﹤0.01%	3575
2021 Q3	$4.86M	Buy	9,172 +1,479	+19%	+$921K	﹤0.01%	3252
2021 Q2	$5.81M	Buy	7,693 +1,829	+31%	+$1.33M	﹤0.01%	3181
2021 Q1	$4.52M	Buy	5,864 +1,643	+39%	+$1.43M	﹤0.01%	3094
2020 Q4	$2.22M	Buy	4,221 +2,522	+148%	+$2.05M	﹤0.01%	3325
2020 Q3	$1.72M	Buy	1,699 +711	+72%	+$1.03M	﹤0.01%	3258
2020 Q2	$1.1M	Buy	+988	New	+$646K	﹤0.01%	3395
2018 Q2	–	Sell	-2	Closed	-$2K	–	3780
2018 Q1	$2K	Hold	2	–	–	﹤0.01%	3751
2017 Q4	$2K	Hold	2	–	–	﹤0.01%	3727
2017 Q3	$4K	Hold	2	–	–	﹤0.01%	3757
2017 Q2	$5K	Hold	2	–	–	﹤0.01%	3691
2017 Q1	$5K	Hold	2	–	–	﹤0.01%	3656
2016 Q4	$5K	Hold	2	–	–	﹤0.01%	3660
2016 Q3	$7K	Hold	2	–	–	﹤0.01%	3586
2016 Q2	$8K	Hold	2	–	–	﹤0.01%	3708
2016 Q1	$7K	Hold	2	–	–	﹤0.01%	3710
2015 Q4	$7K	Hold	2	–	–	﹤0.01%	3704
2015 Q3	$8K	Hold	2	–	–	﹤0.01%	3701
2015 Q2	$12K	Hold	2	–	–	﹤0.01%	3696
2015 Q1	$10K	Hold	2	–	–	﹤0.01%	3658
2014 Q4	$8K	Sell	2 -1	-33%	-$5.34K	﹤0.01%	3683
2014 Q3	$8K	Hold	3	–	–	﹤0.01%	3673
2014 Q2	$6K	Hold	3	–	–	﹤0.01%	3636
2014 Q1	$7K	Hold	3	–	–	﹤0.01%	3636
2013 Q4	$4K	Hold	3	–	–	﹤0.01%	3629
2013 Q3	$6K	Hold	3	–	–	﹤0.01%	3622
2013 Q2	$6K	Buy	+3	New	+$6.91K	﹤0.01%	3569

Other funds holding IBIO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

State Street's IBIO Position: Q1 2026 in Review

State Street increased its iBio (IBIO) stake by 94% in Q1 2026, buying an estimated $158K and bringing the position to 141,199 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #3820.

State Street first reported a position in IBIO in Q2 2013 and has held it in 39 quarters since. The position peaked at $5.81M in Q2 2021. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

State Street held 141,199 shares of iBio worth $268K as of Q1 2026.
State Street bought 68,300 iBio shares in Q1 2026, an estimated $158K.
iBio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3820 holding.
State Street first reported a position in iBio in Q2 2013 and has held it in 39 quarters since.
State Street's iBio position peaked at $5.81M in Q2 2021.
52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.